The ALINA study further validated this by showing that, in patients with stage IB to IIIA ALK-positive NSCLC, adjuvant treatment with alectinib after complete resection reduced the risk of disease recurrence by 76% compared to chemotherapy (DFS HR=0.24, 95% CI 0.13–0.43, P<0.0001). This evidence concerns the gene ALK and non-small cell lung carcinoma.